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Abstract
Background: Prison health systems are subject to increasing pressures given the specific health needs of a growing
and aging prison population. Identifying the drivers of medical spending among incarcerated individuals is therefore
key for health care governance in prisons. This study assesses the determinants of individual health care expenditures
within the prisons of the canton of Vaud, a large region of Switzerland.
Methods: We use a unique dataset linking demographic and prison stay characteristics as well as objective measures
of morbidity to detailed medical invoice data. We adopt a multivariate regression approach to model total, somatic
and psychiatric outpatient health care expenditures.
Results: We find that chronic infectious, musculoskeletal and skin diseases are strong predictors of total and somatic
costs. Schizophrenia, neurotic and personality disorders as well as the abuse of illicit drugs and pharmaceuticals drive
total and psychiatric costs. Furthermore, cumulating psychiatric and somatic comorbidities has an incremental effect on
costs.
Conclusion: By identifying the characteristics associated with health care expenditures in prison, this study constitutes
a key step towards a more efficient use of medical resources in prison.
Keywords: Prison, Health care expenditures, Outpatient care, Chronic diseases
Background
Health care expenditures represent an increasing share
of public spending and constitute a pressing concern in
many developed countries. In correctional systems, these
trends are likely to be exacerbated given the growth,
aging, and specific health needs of the prison population
[1, 2]. In Switzerland, the share of the population in
prison has remained relatively stable at 85 individuals
per 100,000 inhabitants in 2014, which is lower than the
OECD average of about 150 [3]. However, the absolute
number of incarcerated individuals increased by 25%
between 2000 and 2014 [4]. As in most European
countries, the principle of equivalence of care applies,
meaning that all individuals in prison have the right to
access the same standards of quality of health care as
the general population [5–7]. Hence, prison systems are
required to meet the health needs of individuals in
prison with limited resources and while facing important
organizational and ethical challenges.
The prison population has a high prevalence of
chronic somatic and psychiatric conditions as well as
substance abuse problems and infectious diseases [8–
11]. Unmet needs prevail due to low socioeconomic
status, precarious life experience, and limited access to
health care prior to incarceration [12]. These factors
contribute to explaining why health care utilization has
been found to be greater in prison than the general
population [13–19]. Furthermore, developed countries
are witnessing an increase in the share of elderly pris-
oners [20, 21], which stems from harsher sentencing
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patterns with longer incarceration times [22, 23]. Older
individuals in prison naturally have a higher prevalence
of chronic health conditions, serious life-limiting ill-
nesses and comorbidity rates [8, 11, 24]. Aging and
chronic conditions are known to have major economic
consequences on the health care system as a whole
[25, 26]. In particular, non-communicable chronic dis-
eases account for roughly 80% of total annual health
care expenditures in Switzerland [27], with cardiovas-
cular, musculoskeletal and psychiatric diseases being
the largest burdens. Meanwhile, research lacks to
understand the drivers of health care expenditures in
prison. Empirical analyses have been hampered by the
lack of individual-level data linking expenditures and
clinical diagnoses. In light of the demographic trends
and needs outlined above, understanding which factors
are associated with individual health care expenditures
represents a key step towards a more efficient use of
resources and higher standards of care in prison.
This study investigates the determinants of outpatient
health care expenditures in prisons. To this end, we esti-
mate regression models for costs using a unique individual-
level dataset from the canton of Vaud, a large region of
Switzerland. We merge administrative data collected by
prison medical staff with insurance invoice data for incar-
cerated individuals. The administrative data contain infor-
mation on demographics and prison stay as well as a
detailed profile of chronic diseases diagnosed by physicians.
The invoice data capture all medical resources consumed
by the individual within on-site prison outpatient clinics in
2011. This analysis complements previous studies that
examine health care utilization in prisons [14, 17, 18, 28–
32], none of which however consider costs. Our results
show that costs are significantly associated with chronic in-
fectious, musculoskeletal and skin diseases as well as
schizophrenia, neurotic and personality disorders, and the
abuse of illicit drugs and pharmaceuticals. Finally, we show
that cumulating somatic and psychiatric comorbidities
leads to a disproportional increase in costs.
Methods
Data description
This section presents the data, the cost outcomes of
interest and the explanatory variables used to model
them in the multivariate regression analyses. Methodo-
logical details on these analyses are provided in the next
section.
Merged administrative and invoice data
Our analysis links two datasets. First, we use a cross-
sectional dataset on 1664 adult individuals who were in a
closed prison in the canton of Vaud at any point during
the year 2011. The canton of Vaud has one of the largest
prison systems in Switzerland with 641 spaces, that is
about 9% of the total prison capacity in the country during
that period [33]. The administrative data incorporates in-
formation on demographics, prison stay characteristics
(e.g. mode of detention, length of prison stay), health care
utilization, as well as a comprehensive set of objectively
diagnosed chronic somatic and mental health conditions
(see [11] for further details on this data). Each of the four
studied prisons of the canton of Vaud has an on-site out-
patient primary care clinic with nurses, generalist practi-
tioners (GPs), psychiatrists and other visiting specialists,
e.g. gynaecologists and physiotherapists. These clinics are
the main points of provision of health care to individuals
in prison and are operated by the Service of Correctional
Medicine and Psychiatry (SMPP) of the University Hos-
pital of Lausanne (CHUV). These data were systematically
collected and updated by the medical staff of the SMPP.
The Swiss legislation requires an examination by a GP
within 3 weeks of being incarcerated to identify existing
conditions and health needs. The data exclude individuals
who did not have this routine medical examination upon
incarceration and thus missing health data. They also
exclude observations with missing values for any of the
variables used in the empirical analysis.
Second, to obtain health care costs, invoice data were
extracted from the accounting system of the CHUV,
which centralizes all the bills sent to the health insur-
ance companies for outpatient health care provided in
prisons by the SMPP. In Switzerland, outpatient care is
reimbursed through a fee-for-service system, so that in-
voices contain information on all health services pro-
vided and corresponding costs. The fees for outpatient
services in prisons are the same as for the general popu-
lation. The data also include expenses for all medications
delivered on site.
These two datasets are matched to combine individual
information with invoices. While non-matches are ex-
cluded, we retain 106 individuals who are reported not
to have consumed health care in the administrative data
and impute them as zero costs. These either had brief
strays, or entered prison before the beginning of the year
and then did not use health care. Concurrently, there
are several explanations for some of the individuals who
were reported to consume health care in the administra-
tive data not matching with invoice data. The two data-
sets are collected independently, possibly leading to
discrepancies and some bills not being issued. Sample
selection issues related to the matching procedure are
discussed below. The final analysis sample includes 1107
individuals.
Outcome variables: Total, somatic and psychiatric health
care costs
As outcome variables, our regression analyses model
three categories of outpatient health care costs obtained
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from invoice data. First, total costs include all expendi-
tures from medical services used in the on-site out-
patient prison clinics. Costs are cumulated when
individuals have multiple prison stays in 2011. Second,
we split total costs into somatic and psychiatric costs,
corresponding to the two main types of health care pro-
vided in prison. This distinction allows to grasp the
channel through which total costs are affected. The fee-
for-service codes in invoice data are used to identify spe-
cific medical services and allocate them across somatic
and psychiatric categories. Somatic costs comprise GP
consultations, somatic care by nurses, somatic medica-
tion as well as physiotherapy, occupational therapy, and
gynaecological consultations. Medical supplies and diag-
nostic tests are also assigned to somatic care. Psychiatric
costs include consultations with psychiatrists, psychiatric
care by nurses, ambulatory stays at the day psychiatric
clinic and psychotropic drugs. We classify drugs as psy-
chotropic if their Anatomical Therapeutic Chemical
(ATC) classification code begins with N05 or N06, and
as somatic otherwise [34].
Explanatory variables
The administrative data allow us to use a rich set of vari-
ables to model individual health care costs. Our regres-
sions include binary indicators for chronic somatic
diseases, mental health conditions and substance abuse
problems (Table 2), categorized into groups according to
the International Classification of Diseases, version 10
(ICD-10). This allows us to compare the magnitude and
the significance of the influence of each disease group
on costs. While some disease groups may drive up costs
by requiring costly treatment with few contacts with
physicians, others may remain relatively inexpensive des-
pite requiring regular monitoring. Somatic diseases are
diagnosed and reported by a GP, and include infectious
diseases, skin problems, and diseases of the musculo-
skeletal, digestive, circulatory, endocrine, respiratory,
and nervous systems. A psychiatrist reports psychiatric
conditions and substance abuse problems. The former
include schizophrenia, mood disorders, neurotic disor-
ders, behavioural syndromes, personality disorders and
mental retardation. The latter encompass illicit drug,
pharmaceuticals and alcohol abuse.
Regression models also control for sex, age group,
marital status and Swiss origin. A binary indicator for
having health insurance acts as a proxy for socioeco-
nomic status and prior access to health care. Basic
health insurance is mandatory in Switzerland, so that all
residents have to conclude contracts with private health
insurance companies. These contracts are highly regu-
lated and cover a wide range of medical services as
determined by federal law. 1Contracts involve the pay-
ment of monthly premiums, and partial or full means-
tested state subsidies exist to support low-income indi-
viduals. In particular, the insurance covers the costs of
all health services provided in prison. For individuals
with an existing health insurance contract, the premiums
are financed using private funds whenever possible, or
by state subsidies and contributions of the prison admin-
istration. However, more than half of the individuals in
our sample are uninsured, mostly due to an illegal or
highly vulnerable socioeconomic status (e.g. migrants,
marginalized). This points to inequalities in access to
medical care prior to incarceration for uninsured indi-
viduals, to whom prisons may offer an opportunity to
access health care [35]. For these uninsured individuals,
the prison administration directly bears the medical
costs, or purchases basic health insurance on their behalf
in case of longer sentences. Furthermore, in the canton
of Vaud, the prison administration is completely legally
and hierarchically separate from the prison health
services, and does not intervene in medical decisions,
with the exception of court-mandated psychiatric ther-
apies. Prison health services do not pay medical costs
but rather get reimbursed for all the care they provide,
either by the prison administration or health insurance
company. Hence, there should be no incentives for the
prison medical staff to discriminate against individuals
without health insurance, namely to make different
treatment decisions based on insurance status. More-
over, healthcare service provision in Swiss prisons is
governed by the medical and ethical guidelines of the
Swiss Academy of Medical Sciences [36], under the
principle of equivalence of care established by inter-
national norms [6, 37].
We capture prison stay characteristics by including
indicators for the type of crime (sexual, drug-related or
violent, with other as the baseline, e.g. traffic or fraud),
number of stays in 2011 and an indicator for detention
regime (preventive or convicted). We account for length
of stay in 2011 to account for the fact that individuals
with shorter stays have fewer opportunities to consume
health care. Furthermore, total length of stay (including
time spent in prison before 2011) may impact costs,
since anxiety, isolation or withdrawal symptoms evolve
over the incarceration time. Individuals with a shorter
prison experience may consume health care more inten-
sively than those who have stayed longer and had time
to adapt. Concurrently, individuals with longer stays
may need more care due to the psychological burden of
long-term sentences, or conditions acquired in prison
[18, 38]. We also include binary indicators for two
specific types of sentences. First, individuals whose crime
is related to severe mental disorders and high risks of
recidivism are mandated psychiatric treatment under the
Swiss Criminal Code (SCC, article 59) [39]. This meas-
ure can be extended for up to 5 years an unlimited
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number of times. Second, indefinite incarceration may
also be ordered for serious offenders who are highly
prone to recidivism, or are deemed untreatable (SCC,
article 64).
Finally, prison facilities differ by types of detention
regimes, capacity, social environment, and organization
of medical care provision. To capture these differences,
we include binary indicators equal to one if the individ-
ual stayed in a given prison and zero otherwise, consid-
ering that individuals may stay in more than one
facility in a given year (e.g. transfers or multiple stays).
Statistical analysis
Modelling health care costs
As outlined above, we use a multivariate regression
approach to assess the determinants of the health care
costs outcomes described in Section 2.2, using the ex-
planatory variables presented in Section 2.3. Modelling
health care costs poses several challenges due to the
skewness, heavy-tails, and excess zeroes of their distri-
bution. The performance of alternative regression
methods has been widely tested in the econometric lit-
erature [40–46], but no single approach emerges as
the optimal one [47, 48]. However, generalized linear
models (GLMs) offer several advantages in this con-
text. They avoid retransformation issues by estimating
directly on the raw scale, thus accommodating zero
costs and providing interpretable estimates2.
GLMs based on a linear exponential family density
such as Poisson or Gamma can be estimated via
pseudo-maximum likelihood, and provide consistent
estimates as long as the link function (conditional
mean) is correctly specified, even if the true density
does not belong to the linear exponential family [49,
50]. Given this, the choice of the density only affects
efficiency. However, as the link is likely to be misspe-
cified to some extent, the fit will not be equally good
over the whole range of predicted values [41]. GLMs
may suffer from loss of precision with extremely
heavy tails [40], as they impose restrictions on the
whole distribution and do not allow to flexibly model
higher order conditional moments [45, 51].
To select appropriate densities and link functions for
our GLMs, we perform modified Hosmer-Lemeshow,
Pregibon link, Pearson correlation, and modified Park
tests [40, 47]. These tests work with raw-scale residuals
and may be sensible to extreme values. We also conduct
50-fold cross-validation and compute mean prediction
error (MPE), root mean square error (RMSE) and mean
absolute prediction error, which measure the accuracy of
individual predictions [44]. For conciseness, we only
present results of selected tests at the bottom of Table 4.
All models include the length of stay in 2011 as an expos-
ure variable with a coefficient constrained to 1 to account
for differences in opportunities to use care. Finally, robust
sandwich standard errors are estimated to shield us
against misspecifications of the variance [52, 53].
Average partial effects (APEs) of chronic health conditions
and comorbidities
The next step is to determine the magnitude of the
influence of specific chronic diseases and their combina-
tions on costs in monetary terms. To this end, we use
the GLM estimates to compute APEs using the method
of recycled predictions. For each chronic disease c indi-
cator, the APE is computed as
APEc ¼ 1N
X
i
fμ^iðx; 1Þ-μ^iðx; 0Þg
where μ^iðx; cÞ is the predicted conditional mean of
health care costs for individual i holding all other
explanatory variables x constant. Specifically, we first
predict costs for all individuals in the sample with the
disease indicator switched off (equal to 0). Second, we
predict costs for all individuals with the disease indicator
switched on (equal to 1). Third, we average the differ-
ences in predictions across individuals. This approach
provides an estimate of the average difference in costs
from having the particular disease or not across all indi-
viduals and thus avoids covariate imbalance.
We also explore whether comorbidities have a mutu-
ally reinforcing influence on costs. In other words, we
test whether the costs associated with having a given
pair of conditions are greater than the sum of costs asso-
ciated with having each disease separately. In particular,
we focus on pairs of somatic and psychiatric diseases.
Similarly to above, the additional cost of a comorbidity
pair (s, p) is calculated as the average difference in APEs
resulting from switching disease indicators on and off:
APEsp ¼ 1N
X
i
fμ^iðx; 1; 1Þ-μ^iðx; 1; 0Þ−½μ^iðx; 0; 1Þ-μ^iðx; 0; 0Þg
where μ^iðx; s; pÞ is now estimated for combinations of
the somatic condition indicator s and the psychiatric
condition indicator p, holding other explanatory vari-
ables x constant.3
Sample selection
As outlined in Section 2.1, some individuals do not
match across datasets. Hence, our estimates may be sub-
ject to sample selection bias if unobservable factors that
influence the probability of matching are correlated with
health care expenditures. We use the fully robust test
proposed by JM Wooldridge [54] to investigate sample
selection bias in regression models with log link. We
refer the reader to the reference for further details on
this test (p. 666).
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Results
Sample and descriptive statistics
In the data merging procedure, out of the 1664 indi-
viduals present in the administrative data, 1107 (67%)
individuals were matched to invoice data and enter our
final sample, while 557 (33%) were not matched. How-
ever, the test for sample selection does not provide
strong evidence for bias from dropping non-matched
individuals (total costs p-value = 0.051; somatic costs
p-value = 0.300; psychiatric costs p-value = 0.099).
Table 1 presents descriptive statistics of the explana-
tory variables for individuals in our final sample. The
most prevalent chronic somatic conditions are infec-
tious and musculoskeletal diseases. The prevalence of
hepatitis B and C, HIV and tuberculosis is known to be
high among incarcerated individuals [10, 11]. Musculo-
skeletal diseases (mostly back pain) may develop due to
the uncomfortable conditions and lack of physical
activity. Skin problems are also widespread in prison
due to the confined environment [55]. Among psychi-
atric conditions, neurotic and personality disorders are
most common. In terms of demographics, 47% of the
sample consists of male individuals under 30 years old.
Total incarceration length displays large variation and
ranges from 1 day to 11 years in our sample.
Table 2 provides descriptive statistics of total
health care expenditures across several subsamples.
Somatic care represents roughly 30% of total costs,
with almost 40% individuals having at least one
chronic somatic condition. Psychiatric costs account
for 70% of total costs and the proportion of individ-
uals with mental health conditions is 40%. Individ-
uals aged 50 and older are usually defined as elderly
in prison, since they are in worse health than indi-
viduals of the same age in the general population
[24]. Although these older individuals have higher
somatic costs on average, they have lower total and
psychiatric costs than younger individuals. Women
cost more than men in all categories. Individuals
with chronic somatic and psychiatric conditions have
substantially higher expenditures in all categories.
The average total cost for on-site outpatient care is
of CHF 29 per individual per day of incarceration.
These figures show the high degree of variation in
individual costs. However, they are descriptive, and
Table 1 Descriptive statistics of chronic health conditions,
demographics and prison stay characteristics
Proportion in % (N)
Chronic somatic conditions
Infectious diseases 9.2 (102)
Skin problems 6.4 (71)
Musculoskeletal system 10.7 (119)
Digestive system 7.3 (81)
Circulatory system 6.5 (72)
Endocrine system 3.4 (38)
Respiratory system 4.9 (54)
Nervous system 1.5 (17)
Psychiatric conditions
Schizophrenia 2.4 (26)
Mood disorders 2.1 (23)
Neurotic disorders 16.0 (177)
Behavioural syndromes 1.7 (19)
Personality disorders 12.4 (137)
Mental retardation 2.4 (26)
Substance abuse
Alcohol 9.8 (109)
Illicit drugs 17.5 (194)
Pharmaceuticals 5.7 (63)
Demographic characteristics
Aged 18-29a 49.7 (550)
Aged 30–39 28.2 (312)
Aged 40–49 15.7 (174)
Aged 50 and older 6.4 (71)
Malea 92.3 (1022)
Female 7.7 (85)
Married 20.1 (223)
Swiss origin 17.5 (194)
Has health insurance 42.6 (472)
Prison stay characteristics
Stayed in Bois-Mermet prison 37.6 (419)
Stayed in Plaine d’Orbe prison 14.4 (159)
Stayed in Croisée prison 50.5 (559)
Stayed in La Tuilière prison 11.6 (128)
Other type of crimea 69.3 (761)
Violent crime 2.8 (33)
Sexual crime 3.0 (31)
Drug-related crime 25.5 (282)
Convicteda 54.5 (603)
Preventive detention 45.5 (504)
Under SCC article 59 1.4 (16)
Under SCC article 64 0.3 (3)
Table 1 Descriptive statistics of chronic health conditions,
demographics and prison stay characteristics (Continued)
Proportion in % (N)
Number of stays in 2011b 1.3 (0.6)
Total length of stay in 2011 in daysb 97.5 (93.9)
Total incarceration time in daysb 129.4 (239.3)
N = 1107. a Reference categories in regression models. b Mean (SD) for
continuous variables. SCC: Swiss Criminal Code
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the observed relationships may be influenced by con-
founding factors, such as length of stay or health
profile. The regression analysis in the next section
provides evidence on the specific characteristics as-
sociated with costs.
Results of cost regression models
Table 3 reports the exponentiated coefficients of Pois-
son and Gamma GLMs with log link for each cost out-
come. These densities performed better overall in our
selection tests, and are commonly used to model
health care expenditures [42, 43]. The log link enables
a direct interpretation of exponentiated coefficients as
the multiplicative effect on the outcome of a unit
change in the explanatory variable. Comparing these
two models for the three cost categories allows us to
test the sensitivity of results to the choice of the dens-
ity. The modified Park test and the predictive accuracy
measures favour the Poisson model for total and psy-
chiatric costs, which also performs better than the
Gamma GLMs in the other tests. The choice is less
clear for somatic costs. The Hosmer-Lemeshow test
has significant p-values in most cases, and the negative
cross-sample MPE suggests that the models over-
estimate expenditures on average, particularly in the
upper end of the cost distribution4.
Chronic somatic conditions
Chronic infectious, skin and musculoskeletal diseases are
associated with increased total costs in the Poisson model,
and increased somatic costs in both GLMs. Having an
infectious disease multiplies total costs by a factor of
roughly 2.5, which is related to treatments being particu-
larly expensive for these conditions. Circulatory diseases
significantly increase somatic costs, while endocrine
diseases are significant in the Gamma model only.
Respiratory, digestive and nervous system diseases are not
significant.
Interestingly, we also find a positive association between
somatic diseases and psychiatric costs, which suggests that
they partly capture the effect of psychiatric conditions or
substance abuse problems. For example, individuals with
psychiatric disorders and those who inject drugs may dis-
play more behavioural risk factors and comorbidity [35],
making them prone to infectious diseases [56]. Out of the
102 individuals with infectious diseases in our sample, 59
have a substance addition, and 31 have a comorbid psychi-
atric disorder. These results point to an incremental cost
of having both somatic and psychiatric diseases, which we
explore further below.
Mental health conditions and substance abuse problems
Schizophrenia is a strong predictor of psychiatric and
total expenditures, along with neurotic and personality
Table 2 Descriptive statistics of health care costs by subsamples
Cumulated costs (CHF) Total cost per day of
incarceration (CHF)
Length of stay
in 2011 (days)Total Somatic Psychiatric
Sample (N) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
All (1107) 2217 (5416) 660 (2302) 1557 (4465) 28.73 (82.79) 97 (94)
Positive costs onlya 2483 (5645) 749 (2439) 1734 (4679) 31.77 (86.51) 104 (93)
Age group
Under 50 (1036) 2225 (5536) 645 (2351) 1580 (4580) 27.01 (67.48) 98 (94)
Aged 50 and older (71) 2105 (3225) 873 (1388) 1232 (2164) 53.80 (200.73) 95 (100)
Gender
Male (1022) 2140 (5360) 598 (1891) 1542 (4589) 26.78 (77.91) 99 (95)
Female (85) 3142 (6008) 1402 (5069) 1740 (2542) 52.16 (125.91) 84 (75)
Chronic somatic conditions
None (681) 1317 (3628) 307 (476) 1010 (3307) 21.06 (58.01) 83 (88)
One or two (345) 3496 (7393) 1083 (3091) 2413 (6160) 40.19 (114.26) 116 (97)
Three or more (81) 4339 (6342) 1823 (5199) 2516 (3579) 44.40 (93.22) 139 (105)
Psychiatric conditions or substance abuse
None (672) 841 (2561) 492 (2325) 349 (724) 20.19 (91.28) 79 (87)
One or more (435) 4343 (7561) 919 (2243) 3425 (6650) 41.93 (65.54) 126 (98)
At least one somatic and one psychiatric
condition or substance abuse (226)
5297 (8651) 1268 (2996) 4029 (7494) 43.13 (62.08) 139 (100)
aThe means for total cost and length of stay only include the 1001 individuals with positive total costs. The means for somatic and psychiatric costs include 975
and 994 individuals with positive costs, respectively
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disorders. Conversely, mood and behavioural disor-
ders, which include diseases such as depression or
anxiety, have coefficients below one or non significant
for psychiatric and total costs. Behavioural syndromes
are associated with significantly lower somatic costs.
Psychiatric therapies are expensive, as they require
face-to-face sessions with a specialist and costly
psychotropic medication. The coefficients on illicit
drugs and pharmaceuticals abuse are highly signifi-
cantly positive for psychiatric and total costs. Sub-
stance addicts are often enrolled in methadone
maintenance treatment programs managed by psychia-
trists. Illicit drug abuse diminishes somatic costs in
the Poisson model.
We also find positive associations between psychiatric
disorders and somatic costs, which may have several
explanations. Individuals with psychiatric disorders or
substance abuse problems may be less autonomous in
health self-management and particularly susceptible to
violence and self-harm, thus increasing the need for
consultations with GPs or nurses. Also, the use of psy-
chotropic medication may induce metabolic side effects
requiring somatic surveillance [57].
Demographic characteristics
Age is a strong predictor of costs in Gamma GLMs.
Being aged 50 or older is associated with doubled total
and somatic costs, and tripled psychiatric costs relative
to the 18–29 year-old baseline. The pattern is less clear
in Poisson models, which predict higher costs for indi-
viduals aged 30–39 and 40–49, but not for those aged
50 or older. Age is known to be positively associated
with morbidity in both the general and the prison
population [11]. Hence, the chronic disease indicators
partially capture the influence of age on costs.
All else being equal, women have significantly lower
total and psychiatric expenditures in Poisson models,
despite their high prevalence of mental disorders and
infectious diseases [11]. For somatic costs, the coeffi-
cients are above one but not significant. Previous stud-
ies find mixed evidence for women seeking more care
relative to men in prison [14, 15, 28, 31]. However, they
have underlined the specific needs of women in prison,
which prison medical services are often not designed to
satisfy. Marital status is not significant, while being of
Swiss origin is associated with higher psychiatric and
total costs in Gamma models. A possible explanation is
that these individuals are more likely to have followed a
therapy prior to incarceration, so that their conditions
are more easily identified. Also, 44% of drug abusers
and 63% of individuals with mandated psychiatric treat-
ment are Swiss in our sample, so that these characteris-
tics are correlated. These groups are prone to have a
worse health status.
Insurance status is not a significant predictor of ex-
penditures. This suggests that there is no discrimination
in health care access across individuals in prison in
terms of insurance status, and that having had easier ac-
cess to health care prior to incarceration appears to have
no direct impact on health care expenditures in prisons.
Prison stay characteristics
The total length of stay in prison is significantly nega-
tive, with an additional day in prison being associated
with costs lower by 0.1–0.3%. This suggests that ex-
penditures accumulate more slowly as the individual
adapts to the prison environment. The number of
stays does not affect costs. Having committed a violent
crime displays no strong association, while crimes of a
sexual nature are associated with larger total and
psychiatric costs, as sexual offenders often follow a
psychiatric therapy. Drug-related offences are nega-
tively related to expenditures, but are significant in
Gamma models only. Note that the characteristics of
drug dealers may differ from those of consumers. Be-
ing mandated psychiatric treatment is associated with
significantly higher total and psychiatric expenditures,
while being incarcerated indefinitely displays no asso-
ciation. Individuals under preventive detention have
higher costs, which may be explained by the shock of
incarceration or the stress related to on-going judi-
ciary proceedings. Their health status may also deteri-
orate due to them spending almost all day in their cell.
Finally, estimations show that prison indicators are
significant, which points to heterogeneity across facil-
ities being correlated with health care costs.
Average partial effects
Table 4 shows the APEs of chronic conditions on total
costs expressed in Swiss francs (CHF), the scale of inter-
est. Among the somatic disease groups, infectious dis-
eases have the greatest APE and are associated with
increases in total costs of about CHF 3200 to 4500.
Schizophrenia is the costliest psychiatric disorder and
induces expenditures between CHF 3100 and 4400.
APEs vary across GLMs, with greater differences for dis-
eases with large coefficients.
Table 5 displays the additional expenditures generated
by selected comorbidity pairs of chronic somatic and
psychiatric diseases. Specifically, it presents the differ-
ence in the APE of each disease associated with also suf-
fering from the other condition in the pair. The results
suggest that it costs approximately CHF 4600 more to
treat infectious diseases for individuals with schizophre-
nia compared to those without schizophrenia. Infectious
diseases also have significant comorbidity costs in com-
bination with the other psychiatric disorders. Neurotic
disorders and pharmaceuticals abuse induce additional
Moschetti et al. BMC Health Services Research  (2018) 18:160 Page 9 of 13
costs when cumulated with skin or musculoskeletal dis-
eases. Circulatory diseases do not generate comorbidity
costs with psychiatric conditions. These results are in
line with previous evidence for the general population
showing that the incremental cost of an additional
chronic disease increases with the number of existing
conditions [58].
Discussion
This study explores the drivers of individual health
care expenditures for outpatient care within the
prisons of the canton of Vaud, Switzerland. We con-
struct a unique individual-level dataset by combining
detailed invoice data with a wide set of objective mea-
sures of morbidity as well as demographic and prison
stay information. We run regression models to assess
the magnitude and significance of the associations
between these characteristics and total, somatic and
psychiatric health care expenditures. Furthermore, cal-
culating the APEs allows the estimation of the eco-
nomic impact of chronic conditions as well as the
additional costs of cumulating psychiatric and somatic
comorbidities.
This paper adds to the scarce literature on the health
profile and health care utilization of incarcerated
individuals.
The results provide key insights into the costs of
medical resources provided in prison, and inform the
allocation of scarce financial resources in prisons by
identifying individual characteristics and health con-
ditions that predict higher expenditures. A more effi-
cient identification of individuals who present these
characteristics may significantly improve their man-
agement and outcomes, and subsequently lead to
lower expenditures. In our sample, less than 100 indi-
viduals induce more than half of the total on-site out-
patient costs. From the perspective of the prison
administration, the results provide relevant informa-
tion to identify those individuals, for whom health
insurance should be purchased rapidly.
Table 4 Average partial effects of chronic health conditions on
total costs (in CHF)
Poisson-log GLM Gamma-log GLM
APE (SE) APE (SE)
Chronic somatic conditions
Infectious diseases 3226*** (710) 4540*** (1448)
Skin problems 1054** (479) 2390* (1434)
Musculoskeletal system 711** (292) 2496*** (966)
Digestive system −291 (247) 280 (467)
Circulatory system 1272 (1125) 2089 (1364)
Endocrine system 315 (624) 582 (897)
Respiratory system −245 (320) − 695* (419)
Nervous system 465 (609) 1865 (1217)
Psychiatric conditions
Schizophrenia 3138*** (878) 4422*** (1548)
Mood disorder 210 (427) − 469 (598)
Neurotic disorder 1308*** (318) 1920*** (501)
Behavioural syndrome −197 (381) − 183 (623)
Personality disorder 907*** (340) 836* (440)
Mental retardation 569 (797) 670 (752.)
Substance abuse
Alcohol 65 (260) 1076** (480)
Illicit drugs 578** (282) 2495*** (784)
Pharmaceuticals 1877*** (554) 2507** (1009)
N = 1107. Standard errors calculated with the delta-method. Length of stay in
2011 (exposure) taken into account. * p < 0.10, ** p < 0.05, *** p < 0.01
Table 5 Average partial effects of selected comorbidities on total costs (in CHF)
Infectious diseases Skin problems Musculoskeletal diseases Circulatory diseases
APE (SE) APE (SE) APE (SE) APE (SE)
Psychiatric conditions
Schizophrenia 4576*** (1681) 1487* (883) 1005* (536) 1795 (1452)
Mood disorder 306 (613) 100 (211) 67 (136) 121 (236)
Neurotic disorder 1893*** (607) 621** (316) 419** (210) 753 (623)
Behavioral syndrome −287 (552) −94 (180) −63 (126) −113 (247)
Personality disorder 1318** (586) 431 (286) 291* (164) 521 (449)
Mental retardation 827 (1166) 271 (383) 183 (254) 327 (541)
Substance abuse
Alcohol 95 (379) 31 (126) 21 (83) 37 (149)
Illicit drugs 853** (372) 275 (180) 185* (109) 331 (303)
Pharmaceuticals 2750** (1017) 894** (427) 602** (305) 1075 (1058)
N = 1107. Standard errors calculated with the delta-method. Length of stay in 2011 (exposure) taken into account
* p < 0.10, ** p < 0.05, *** p < 0.01
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Among somatic diseases, we identify chronic infec-
tious diseases, musculoskeletal and skin problems as
important predictors of health care expenditures
within prisons. Infectious diseases in particular remain
a serious issue in correctional facilities and an import-
ant target for prevention. Schizophrenia, neurotic and
personality disorders as well as illicit drugs and phar-
maceuticals abuse are significantly associated with
increased total and psychiatric costs. Furthermore,
individuals cumulating somatic and psychiatric condi-
tions induce additional costs directly related to the co-
morbidity itself. Hence, the high predisposition of
individuals with psychiatric and substance abuse disor-
ders towards risky health behaviours make them a
particularly pertinent target group. Psychotropic treat-
ments may also cause somatic side effects that are dif-
ficult to manage in prisons. These considerations
underscore the importance of coordination between
psychiatric and somatic health care professionals.
More generally, the incremental costs of comorbidities
are an increasingly relevant issue both in prisons and
in the general population.
Prison infrastructures and health systems are often not
designed to manage somatic chronic conditions effi-
ciently, which may exacerbate their impact [59]. Regular
follow up consultations with nurses and GPs are compli-
cated by security and logistic concerns, adding indirect
costs to those of medical care. The need for consulta-
tions is increased in prison since, unlike the general
population, incarcerated individuals cannot benefit from
informal health care contacts, e.g. with relatives or phar-
macists [15, 16]. In this context, prevention can contrib-
ute to avoid developing or worsening of chronic illnesses
– along with costly complications and comorbidities –
and to contain costs. In particular, fostering health liter-
acy and informing individuals in prison on how to man-
age their chronic somatic conditions may increase
treatment adherence and outcomes, while reducing the
need for medical contacts. Additionally, ensuring con-
tinuity of treatment both outside of the prison and
throughout the incarceration period may favour reinte-
gration and socioeconomic stability upon release, as well
as decrease the probability of costly acute complications.
An interesting feature of the environment under
study is the absence of inequalities in access to health
care. Indeed, the medical services offered in prison are
relatively standardized, and the institutional setting
eliminates the direct role of financial enabling factors,
since incarcerated individuals incur no out-of-pocket
costs. This differs from the general population, which
typically faces inequalities in access to and quality of
care related to socioeconomic status. However, individ-
uals in prison have specific needs and therefore are not
a representative subgroup of the general population.
For example, individuals in prison may consult medical
staff because of difficulties to adjust to the correctional
environment, a wish to relieve boredom, or the hope to
obtain psychotropic drugs, which have resale value
within prisons. Organizational constraints also exist
that may create a wedge between the desirable and ac-
tual levels of health care utilization. Finally, the absence
of provider choice in prison and competition mecha-
nisms could limit incentives to improve quality of care
and contain costs.
Limitations and strengths
This analysis has several limitations. First, with regards
to captured costs, our data do not include costs gener-
ated by off-site health care services, namely specialized
outpatient care unavailable on-site, emergency admis-
sions or inpatient care. Complete cost data were not
available for these services since providers other than
the CHUV may supply them. Off-site care is typically
costly, primarily because concerned individuals require
emergency admissions or hospital stays and are usually
more severe. Off-site transfers also involve complex
security measures and generate further non-medical ex-
penses. However, off-site care complements rather than
substitutes regular outpatient care in prison clinics, since
prison medical staff act as gatekeepers for off-site care
and are responsible for subsequent follow ups. Not ac-
counting for these off-site is thus unlikely to deflate (or
shift) the on-site costs. Furthermore, on-site outpatient
care represents more than 95% of the total number of
outpatient consultations, making this study highly rele-
vant for prison health care governance. Further research
aiming at evaluating individual risk factors for off-site
health care utilization would be pertinent.
As for the on-site outpatient care under study, it is
possible that some services were not entered into the ac-
counting system, so that costs may be underestimated.
In particular, short visits to nurses for routine blood
pressure level checks or medication administration may
have been overlooked. These are likely to represent low
costs, and there is no reason to believe that billing de-
pends on any individual characteristics so as to bias our
estimates. Another limitation of our data and hence our
models is that we do not include acute episodes such as
influenza or hunger strikes. However, chronic conditions
generate a substantial part of these acute complications
(e.g. blood sugar drops for individuals with diabetes, or
self-harm for individuals suffering from depression). Fi-
nally, data are available only for one region of
Switzerland, which limits external validity.
Conclusion
Prisons play a crucial role in addressing the medical
needs of incarcerated individuals, whose access to health
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care prior to detention is often limited. Most of them
are eventually released, so that poorly managed health
problems may additionally burden the health care sys-
tem outside the prison [12]. In light of the high disease
prevalence even in young prison populations, the pres-
sures on prison health systems are bound to increase as
the population grows and ages. While this study pro-
vides insights into the patterns of individual health care
expenditures in prison, further evidence on the cost-
effectiveness and organization of prison health care
provision is key to ensure adequate quality of care for
incarcerated individuals as well as working conditions
for prison staff. Data availability in correctional settings
remains a challenge to progress in this area.
Endnotes
1For further details on the Swiss health and insurance
systems, see e.g., the review published by the OECD and
the WHO [60].
2Ordinary least squares of log-transformed expendi-
tures are commonly used and may be efficient with
heavy-tailed data [40]. However, this method poses the
retransformation problem to obtain interpretable results,
especially in the presence of heteroscedasticity, and is
inappropriate for zero data. Breusch-Pagan and White
tests detect complex heteroscedasticity of log-scale
residuals, and the Shapiro-Wilk test rejects normality
(all p-values < 0.000).
3We experimented with models including interaction
terms between disease indicators, but these led to severe
collinearity issues.
4Plotting the mean residuals by deciles of costs indi-
cates that the models consistently over-predict in the
upper decile. The Gamma model in particular down-
weighs the errors at the high end of costs compared to
the Poisson model, which gives equal weight to errors
across the whole range. Therefore, the Gamma fits high-
cost observations worse [41].
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